Tetanus Antitoxoid Antibodies
| Tetanus Antitoxoid Antibodies | | | |
| Number | | 163691 |
| CPT | | 86317 |
| Synonyms | | Tetanus Antibodies ; Tetanus Toxin Antibodies |
| Specimen | | Serum |
| Volume | | 0.4 mL |
| Minimum Volume | | 0.2 mL |
| Container | | Gel-barrier tube or red-top tube |
| Storage Instructions | | Refrigerate |
| Causes for Rejection | | Gross hemolysis; lipemia; bacterial contamination |
| Reference Interval | | Nonprotective: <0.1 IU/mL |
| Use | | Assess immunity against tetanus by determining levels of circulating antibodies to tetanus toxin or to measure the immune response, postvaccination, in individuals suspected of immunodeficiency disorders |
| Limitations | | Determination of tetanus toxoid antibodies is of no value in assessing the need for prophylactic or therapeutic management. Immunity declines with age, and boosters are recommended every 10 years. This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients. |
| Methodology | | Enzyme immunoassay (EIA) |
| References | | Gergen PJ, McQuillan GM, Kiely M, et al, “A Population-Based Serologic Survey of Immunity to Tetanus in the United States,” N Engl J Med, 1995, 332(12):761-6. Rose NR, Manual of Clinical Immunology, 5th ed, Washington, DC: ASM [American Society for Microbiology] Press, 1997, 470-2. |
|